Ignacio Rivero Berti

Dr. Ignacio Rivero Berti


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MHManuel Horue
Manuel Horue
JSJhonatan Miguel Silva
Jhonatan Miguel Silva
IBIgnacio Rivero Berti
Ignacio Rivero Berti
LBLarissa Reis Brandão
Larissa Reis Brandão
Hernane Silva BarudHernane Silva Barud
Hernane Silva Barud
Guillermo Raul CastroGuillermo Raul Castro
Guillermo Raul Castro
Bacterial cellulose (BC) is produced by several microorganisms as extracellular structures and can be modified by various physicochemical and biological strategies to produce different cellulosic formats. The main advantages of BC for biomedical applications can be summarized thus: easy moldability, purification, and scalability; high biocompatibility; and straightforward tailoring. The presence of a high amount of free hydroxyl residues, linked with water and nanoporous morphology, makes BC polymer an ideal candidate for wound healing. In this frame, acute and chronic wounds, associated with prevalent pathologies, were addressed to find adequate therapeutic strategies. Hence, the main characteristics of different BC structures—such as membranes and films, fibrous and spheroidal, nanocrystals and nanofibers, and different BC blends, as well as recent advances in BC composites with alginate, collagen, chitosan, silk sericin, and some miscellaneous blends—are reported in detail. Moreover, the development of novel antimicrobial BC and drug delivery systems are discussed.

2 August 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Carolina Medina-MontanoCarolina Medina-Montano
Carolina Medina-Montano
IBIgnacio Rivero Berti
Ignacio Rivero Berti
RGRocío C. Gambaro
Rocío C. Gambaro
MLMaría José Limeres
María José Limeres
MSMalin Svensson
Malin Svensson
Maximiliano Luis CacicedoMaximiliano Luis Cacicedo
Maximiliano Luis Cacicedo
Liver inflammation represents a major clinical problem in a wide range of pathologies. Among the strategies to prevent liver failure, dexamethasone (DXM) has been widely used to suppress inflammatory responses. The use of nanocarriers for encapsulation and sustained release of glucocorticoids to liver cells could provide a solution to prevent severe side effects associated with systemic delivery as the conventional treatment regime. Here we describe a nanostructured lipid carrier developed to efficiently encapsulate and release DXM. This nano-formulation proved to be stable over time, did not interact in vitro with plasma opsonins, and was well tolerated by primary non-parenchymal liver cells (NPCs). Released DXM preserved its pharmacological activity, as evidenced by inducing robust anti-inflammatory responses in NPCs. Taken together, nanostructured lipid carriers may constitute a reliable platform for the delivery of DXM to treat pathologies associated with chronic liver inflammation.